The future possibilities for Nanogen's molecular diagnostics business broadened last week when Fisher Scientific spent $15 million to buy a 9-percent stake in the San Diego-based company.

The purchase, which makes Fisher one of Nanogen's lead investors, coincided with Fisher's $283-million acquisition of Athena Diagnostics and a plan by Fisher and Nanogen to develop and sell Athena's tests. Athena, based in Worcester, Mass., makes immunohistochemical and molecular diagnostics for neurological, nephrologic, and endocrine diseases.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The UK's Nuffield Council on Bioethics says genetically modifying human embryos could be morally permissible, according to the Guardian.

A new Nature Biotechnology paper reports that CRISPR-Cas9 gene editing can lead to large deletions or complex rearrangements that could be pathogenic.

The Wall Street Journal likens a prototype developed by Synthetic Genomics to a "biological fax machine."

In PNAS this week: strategy for reactivating Rett syndrome-linked MECP2, small molecules able to suppress Staphylococcus aureus virulence, and more.